<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Epidemiology</journal-id><journal-id journal-id-type="iso-abbrev">Epidemiology</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Epidemiology (Cambridge, Mass.)</journal-title></journal-title-group><issn pub-type="ppub">1044-3983</issn><issn pub-type="epub">1531-5487</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10841877</article-id><article-id pub-id-type="pmcid-ver">PMC10841877.319</article-id><article-id pub-id-type="pmcaid">10841877</article-id><article-id pub-id-type="pmcaiid">10841877</article-id><article-id pub-id-type="manuscript-id">NIHMS1935575</article-id><article-id pub-id-type="pmid">37820243</article-id><article-id pub-id-type="doi">10.1097/EDE.0000000000001681</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1935575</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1935575</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Medications for opioid use disorder and mortality and hospitalization among people with opioid use-related infections</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Figgatt</surname><given-names initials="MC">Mary C</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hincapie-Castillo</surname><given-names initials="JM">Juan M</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schranz</surname><given-names initials="AJ">Asher J</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dasgupta</surname><given-names initials="N">Nabarun</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Edwards</surname><given-names initials="JK">Jessie K</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jackson</surname><given-names initials="BE">Bradford E</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marshall</surname><given-names initials="SW">Stephen W</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Golightly</surname><given-names initials="YM">Yvonne M</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A6" ref-type="aff">6</xref></contrib></contrib-group><aff id="A1"><label>1)</label>University of North Carolina at Chapel Hill Gillings School of Global Public Health Department of Epidemiology, 135 Dauer Drive, Chapel Hill, North Carolina, USA, 27599.</aff><aff id="A2"><label>2)</label>University of North Carolina Injury Prevention Research Center, 725 Martin Luther King Jr Blvd, Chapel Hill, North Carolina, USA, 27599.</aff><aff id="A3"><label>3)</label>University of North Carolina at Chapel Hill School of Medicine Division of Infectious Diseases, Chapel Hill, 130 Mason Farm Road, Chapel Hill, North Carolina, USA, 27599.</aff><aff id="A4"><label>4)</label>University of North Carolina at Chapel Hill Gillings School of Global Public Health, 135 Dauer Drive, Chapel Hill, North Carolina, USA, 27599.</aff><aff id="A5"><label>5)</label>University of North Carolina Lineberger Cancer Center Cancer Information and Population Health Resource, 101 East Weaver St, Chapel Hill, North Carolina, USA, 27599.</aff><aff id="A6"><label>6)</label>University of Nebraska Medical Center College of Allied Health Professions, 42<sup>nd</sup> and Emilie St, Omaha, Nebraska, USA, 68198.</aff><author-notes><corresp id="CR1"><bold>Corresponding author:</bold> Mary C Figgatt, University of North Carolina at Chapel Hill Gillings School of Global Public Health Department of Epidemiology, 135 Dauer Drive, Chapel Hill, North Carolina, USA, 27599, 484-947-3564, <email>mfiggatt@unc.edu</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P34"><bold>Conflicts of interest:</bold> Author Nabarun Dasgupta of this publication has editorial relationship with the American Journal of Public Health, which is published by APHA. This relationship has been disclosed to UNC-Chapel Hill.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>1</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>11</day><month>10</month><year>2023</year></pub-date><volume>35</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">455061</issue-id><fpage>7</fpage><lpage>15</lpage><pub-history><event event-type="nihms-submitted"><date><day>11</day><month>10</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-01 00:26:13.670"><day>01</day><month>01</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1935575.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P1">Severe skin and soft tissue infections related to injection drug use have increased in concordance with a shift to heroin and illicitly manufactured fentanyl. Opioid agonist therapy medications (methadone and buprenorphine) may improve long-term outcomes by reducing injection drug use. We aimed to examine the association of medication use with mortality among people with an opioid use-related skin or soft tissue infections.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">An observational cohort study of Medicaid enrollees aged 18 years or older following their first documented medical encounters for opioid use-related skin or soft tissue infections during 2007-2018 in North Carolina. The exposure was documented medication use (methadone or buprenorphine claim) in the first 30 days following initial infection compared to no medication claim. Using Kaplan&#8211;Meier estimators, we examined the difference in 3-year incidence of mortality by medication use, weighted for year, age, comorbidities, and length of hospital stay.</p></sec><sec id="S3"><title>Results:</title><p id="P3">In this sample, there were 13,286 people with opioid use-related skin or soft tissue infections. The median age was 37 years, 68% were women, and 78% were white. In Kaplan&#8211;Meier curves for the total study population, 12 of every 100 patients died during the first 3 years. In weighted models, for every 100 people who used medications, there were 4 fewer deaths over 3 years (95% confidence interval:2 to 6).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">In this study, people with opioid use-related skin and soft tissue infections had high risk of mortality following their initial healthcare visit for infections. Methadone or buprenorphine use was associated with reductions in mortality.</p></sec></abstract><kwd-group><kwd>Opioid use disorder</kwd><kwd>skin infections</kwd><kwd>methadone</kwd><kwd>buprenorphine</kwd><kwd>mortality</kwd><kwd>hospitalization</kwd><kwd>injection drug use</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>